From: The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis
No plaque | Plaque | |||||
---|---|---|---|---|---|---|
Factor | Total N assessed | N | Statistics | N | Statistics | p valuea |
Ageb | 87 | 53 | 49.58 ± 10.56 | 34 | 58 ± 8.58 | <0.001T |
Male sexc | 87 | 26 | 49.06 | 15 | 44.12 | 0.82C |
History of hypertensionc | 86 | 17 | 32.69 | 23 | 67.65 | 0.003C |
BP < 140/90 mmHgc | 87 | 42 | 79.25 | 20 | 58.82 | 0.07C |
Smoking statusc | 87 | 0.052C | ||||
No | 44 | 29 | 54.72 | 15 | 44.12 | |
Former | 26 | 18 | 33.96 | 8 | 23.53 | |
Current | 17 | 6 | 11.32 | 11 | 32.35 | |
BMIb | 79 | 47 | 30.87 ± 8.54 | 32 | 30.34 ± 6.16 | 0.75T |
Diabetesc | 87 | 7 | 13.21 | 9 | 26.47 | 0.20C |
Total cholesterolb | 75 | 44 | 184.5 ± 29.31 | 31 | 202.48 ± 45.16 | 0.057T |
Triglycerided | 74 | 43 | 95 (70, 125) | 31 | 144 (87.5, 177.5) | 0.014W |
HDLb | 74 | 43 | 55.12 ± 15.49 | 31 | 56.16 ± 21.55 | 0.82T |
LDLb | 74 | 43 | 104.07 ± 26.35 | 31 | 118.74 ± 41.94 | 0.092T |
Antiplatelet usec | 87 | 14 | 26.42 | 10 | 29.41 | 0.95C |
Statin usec | 87 | 9 | 16.98 | 10 | 29.41 | 0.27C |
Biologic usec | 87 | 0.03F | ||||
No | 17 | 14 | 26.42 | 3 | 8.82 | |
Former | 5 | 1 | 1.89 | 4 | 11.76 | |
Current | 65 | 38 | 71.7 | 27 | 79.41 | |
Traditional DMARD usec | 87 | 0.75F | ||||
No | 11 | 7 | 13.21 | 4 | 11.76 | |
Former | 34 | 19 | 35.85 | 15 | 44.12 | |
Current | 42 | 27 | 50.94 | 15 | 44.12 | |
History of CVDc | 87 | 2 | 3.77 | 5 | 14.71 | 0.11F |
ESRd | 69 | 37 | 8 (4, 10) | 32 | 8 (5.25, 12.25) | 0.53W |
CRPd | 84 | 52 | 0.3 (0.1, 0.6) | 32 | 0.3 (0.2, 1.22) | 0.11W |
PsO durationb | 85 | 52 | 21.02 ± 14.79 | 33 | 22.58 ± 19.14 | 0.69T |
PsA durationb | 84 | 51 | 10.76 ± 8.32 | 33 | 12.76 ± 10.7 | 0.37T |
Prednisone use > 1 monthc | 86 | 26 | 49.06 | 11 | 33.33 | 0.23C |
Current NSAID usec | 87 | 27 | 50.94 | 22 | 64.71 | 0.30C |
Baseline SJCd | 81 | 49 | 1 (0, 5) | 32 | 0 (0, 4.5) | 0.88W |
Baseline TJCd | 81 | 49 | 5 (0, 14) | 32 | 5 (0.75, 16.25) | 0.93W |